Sector News

Medtronic names former Amazon robotics VP as technology chief

June 11, 2023
Life sciences

Medtronic has named Ken Washington, former vice president and general manager of consumer robotics at Amazon, to the newly created position of chief technology and innovation officer for the device maker.

Washington will become a member of Medtronic’s executive committee.

He brings extensive experience leading technology development and execution across industries including robotics, consumer products, automotive and space, and will be tasked with accelerating innovation-driven growth, Medtronic said.

“His hiring seems to fit into the larger pattern that [Medtronic CEO] Geoff Martha has established – looking widely outside of medtech for individuals with deep, functional expertise and bringing them over. For instance, Greg Smith joined to lead MDT’s supply chain and he came from Walmart. Que Dallara brought significant software experience from Honeywell’s aeronautics business over to MDT’s diabetes segment,” Morningstar analyst Debbie Wang said in an email. READ MORE

By Susan Kelly


comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach